Analyst firms · J.P. Morgan · YMAB
J.P. Morgan YMAB price target and rating history
Y-mAbs Therapeutics Inc. (YMAB) · Health Care
J.P. Morgan rates Y-mAbs Therapeutics Inc. (YMAB) Underweight with a $7 price target, as of its latest action on Oct 31, 2022. It has published 3 rating actions on YMAB since November 2021, including 0 upgrades and 2 downgrades.
- Current rating
- Underweight
- Price target
- $7
- Median target, all firms
- Too few
- Actions on YMAB
- 3
J.P. Morgan price target on YMAB
Every J.P. Morgan rating on YMAB
- Oct 31, 2022
- Jan 3, 2022
- Nov 16, 2021
Questions about J.P. Morgan and YMAB
- What is J.P. Morgan's price target for YMAB?
- J.P. Morgan's latest stated price target for Y-mAbs Therapeutics Inc. (YMAB) is $7, from its action on Oct 31, 2022.
- What is J.P. Morgan's rating on YMAB?
- J.P. Morgan rates YMAB Underweight, a bearish rating, as of Oct 31, 2022.
- When did J.P. Morgan last change its view on YMAB?
- On Oct 31, 2022, J.P. Morgan downgrades to Underweight from Neutral, price target $16 to $7.
More YMAB rating histories
All J.P. Morgan ratingsYMAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.